Perpetrator Drug | Observed AUCR (90% CI) | Predicted AUCR | ||
---|---|---|---|---|
R3 Averagea (Individualb) | AUCR Averagea (Individualb) | AUCR′c Averagea (Individualb) | ||
ASV (200 mg twice a day) | 0.71 (0.67–0.75) | 0.32 (0.26; 0.31; 0.52) | 2.36 (2.29; 2.37; 2.46) | 0.50 (0.35; 0.54; 0.83) |
ASV (600 mg twice a day) | 0.56 (0.50–0.64) | 0.24 (0.18; 0.24; 0.43) | 3.02 (2.94; 3.01; 3.16) | 0.70 (0.51; 0.75; 1.09) |
DCV (60 mg every day) | 0.87 (0.83–0.92) | 0.18 (0.13; 0.17; 0.32) | 0.43 (0.33; 0.44; 0.68) | —g |
BCV (150 mg twice a day) | 0.50 (0.45–0.57) | 0.17 (0.10; 0.26; 0.31) | 0.53 (0.34; 0.70; 0.72) | —g |
BCV (300 mg twice a day) | 0.44 (0.40–0.48) | 0.14 (0.08; 0.23; 0.27) | 0.55 (0.34; 0.75; 0.77) | —g |
Triple Combination Id | 0.53 (0.47–0.60) | 0.084 (0.06; 0.17) | 1.94 (1.70; 2.12) | 0.33 (0.21; 0.59) |
Triple Combination IIe | 0.42 (0.37–0.48) | 0.078 (0.05; 0.16) | 1.73 (1.45; 1.94) | 0.32 (0.19; 0.58) |
CI, confidence interval.
↵a Model prediction using the average values of EC50 and Emax from Table 3.
↵b Model prediction using the EC50 and Emax of individual donors from Table 2.
↵c Mechanistic static model approach not including the TDI effect of ASV.
↵d ASV (200 mg twice a day); DCV (30 mg twice a day); and BCV (75 mg twice a day).
↵e ASV (200 mg twice a day); DCV (30 mg twice a day); and BCV (150 mg twice a day).
↵g Study did not involve ASV, thus AUCR' value is not applicable.